|
|
|
|
Medizinische Universitäts-Poliklinik, 53111 Bonn, Germany
| |
Summary |
|---|
|
|
|---|
Low-density lipoprotein (LDL) is known to be a mitogenic factor
for vascular smooth muscle cells (VSMCs), fibroblasts, and endothelial cells. In the current study, we describe possible intracellular mechanisms by which LDL elicits its mitogenic effects. Stimulation of VSMCs with LDL resulted in a pertussis-toxin
(PTX)-sensitive stimulation of the 44-kDa mitogen-activated protein
(MAP) kinase (p44mapk) and 42-kDa MAP kinase
(p42mapk) isoforms as well as in a PTX-sensitive increase
in intracellular free Ca2+ concentration
([Ca2+]i). Binding of the LDL-induced
increase in [Ca2+]i to the intracellular
Ca2+ chelator
bis(2-amino-5-methylphenoxy)ethane-N,N,N
,N
-tetraacetic acid tetraacetoxymethyl ester resulted in a 2-fold increase in the
phosphorylated p44mapk and p42mapk isoforms but
did not influence the LDL effect of VSMC DNA synthesis. PD 98059, a MAP
kinase kinase inhibitor, remarkably attenuated the LDL-induced
activation of MAP kinases and DNA synthesis. Treatment of normal human
skin fibroblasts and human fibroblasts isolated from patients with
familial hypercholesterolemia homozygote class 1 mutations, which are
not able to produce the classic LDL receptor, resulted also in a
PTX-sensitive increase in cell DNA synthesis and stimulation of the
p44mapk and p42mapk isoforms in both cell
types. These results demonstrate that the mitogenic effect of LDL is
mediated by a PTX-sensitive Gi-coupled receptor that is
independent of its classic receptor and involves activation of MAP
kinase isoforms. Furthermore, the mitogenic effect of LDL may be
mediated by the activation of the MAP kinase pathway. In contrast, the
LDL-induced increase in [Ca2+]i may be
implicated in this process only in conjugation with other signaling
components.
| |
Introduction |
|---|
|
|
|---|
VSMCs hypertrophy, and proliferation may participate in the pathophysiology of cardiovascular diseases (1). Atherosclerotic lesions result from an excessive, inflammatory-fibroproliferative response to various forms of injury to the endothelium and smooth muscle within the arterial wall (2). The major physiological function of LDL is to deliver cholesterol into cells via binding to its classic receptor (3). LDL is considered to be the main atherogenic class of lipoproteins (4). In addition to its physiological role as a cholesterol transport vehicle and its regulatory function for cholesterol homeostasis, there is evidence that LDL causes general cellular activation and cell proliferation. In this context, it has been shown that LDL stimulates the phosphoinositide catabolism (5), elevates [Ca2+]i, activates the Na+/H+ exchanger (6), and promotes the expression of immediate-early growth response genes such as c-fos (5) and egr-1 (7) in VSMCs. Furthermore, several laboratories reported that LDL per se and in combination with classic growth factors such as PDGF exerts mitogenic effects on VSMCs (6, 8-10) and endothelial cells (9, 11). Recently, an atypical LDL binding site on human VSMCs was characterized that is independent of its classic receptor and may mediate the LDL-induced phosphoinositide catabolism in VSMCs (12).
PDGF is a potent serum factor that promotes the proliferation of
fibroblasts, glial cells, and VSMCs (13, 14) and thus is postulated to
play an important role in the pathogenesis of atherosclerosis (1, 2).
It is established that the classic growth factor PDGF-BB propagates its
mitogenic signals via autophosphorylation of its respective PDGF-
receptor on tyrosine residues, resulting in tyrosine phosphorylation of
different substrate proteins such as PLC-
1, p21ras GTPase
activating protein, and PI3 kinase, carrying SH2
domains that are capable of binding to specific regions of the PDGF-
receptor containing autophosphorylated tyrosine residues (15). There
are several reports demonstrating that the PLC-
pathway induced by
potent VSMC mitogens such as PDGF and FGF might not be essential for
cell DNA synthesis (16, 17). A more important mitogenic signal seems to
be activation of the PI3 kinase that phosphorylates the 3 position of the inositol ring of
phosphatidylinositol-4-monophosphate and
phosphatidylinositol-4,5-biphosphate to produce their respective PI3 phosphorylated metabolites (18, 19);
therefore, the PI3 kinase was an interesting
candidate to investigate whether it is involved in the LDL-induced DNA
synthesis. It has recently been recognized that further transmission of
growth signals from the receptor to the nucleus is mediated by
sequentially activated protein kinases. The activation of MAP kinases,
in particular, the 42-kDa (p42mapk) and the
44-kDa (p44mapk) isoforms, seems to be a key step
in growth signal transduction through tyrosine kinase receptors such as
the PDGF-
receptor (20, 21).
In this context, it is assumed that MAP kinases and PI3 kinase activate S6 protein kinases, in particular the 70-kDa (p70rsk) and the 90-kDa kinase (p90rsk), encoded by the rsk gene family. Stimulation of the S6 protein seems to be the requisite for mitogenic signal transduction. Furthermore, it is postulated that activation of MAP kinases is involved in the growth factor-induced expression of immediate-early genes such as c-fos (20, 21).
It is believed that activation of the MAP kinase isoforms occurs by MEK via threonine and tyrosine phosphorylation, and Raf-1 kinase (a 74-kDa protein kinase encoded by the proto-oncogene raf-1) may be the kinase responsible for activation of MEK (20, 21). In this context, it is assumed that activation of the MAP kinase occurs via a cascade that requires the activation of p21ras, p21ras GTPase activating protein, Raf-1 kinase, and MEK. It is believed that activation of Raf-1 kinase occurs via phosphorylation of several serine and threonine residues of the molecule by the activated c-Ras via an unknown mechanism. It has been proposed that activation of c-Ras occurs by Grb2/Sos. Grb2 is activated by the SH2-adaptor protein Shc, which is activated by tyrosine-phosphorylation in response to growth factors. Alternatively, this cascade may also stimulated by G proteins via activation of MEK kinase independently of the Raf-1 cascade (20, 21).
In contrast to PDGF-BB, agonists such as thrombin and LPA propagate their mitogenic effect in fibroblasts through a PTX-sensitive Gi protein pathway (22-24).
To elucidate whether activation of the MAP kinase pathway is implicated
in LDL-induced DNA synthesis, the effect of LDL on the phosphorylation
of p42mapk and p44mapk
isoforms and DNA synthesis in VSMCs was investigated in the presence and absence of the selective MEK inhibitor PD 98059 [(2-2
-amino-3
-methoxyphenyl)-oxanaphthalen-4-one] (25). To show
whether the effect of LDL on cell growth is mediated by a PTX-sensitive
Gi protein, the effects of PTX on LDL- or
LPA-induced DNA synthesis and intracellular transduction pathways were
investigated. Finally, to demonstrate whether these effects are
mediated by the classic LDL receptor, the effect of LDL on MAP kinase
activity and DNA synthesis in cultured normal human fibroblasts and
human fibroblasts isolated from patients with FH homozygote class 1 mutations was examined. These cells are not able to produce LDL receptor protein as determined by reaction with monoclonal antibodies (3).
| |
Experimental Procedures |
|---|
|
|
|---|
Materials.
Fura-2/pentaacetoxymethyl ester, MAPTAM, and PD
98059 were obtained from Calbiochem (Bad Soden, Germany).
Anti-
-smooth muscle actin was obtained from Sigma Chemical
(Deisenhofen, Germany). FITC-conjugated F(ab
)2
fragment of goat anti-mouse immunoglobulins was obtained from Dako
Diagnostika (Hamburg, Germany). DMEM, Ham's F-10, and
phosphate-buffered saline were obtained from GIBCO BRL (Eggestein,
Germany). FCS was obtained from Boehringer-Mannheim Biochemica
(Mannheim, Germany). PDGF-BB was a gift from Prof. Dr. Jürgen
Hoppe (Department of Physiological Chemistry, University of
Würzburg, Germany) and was prepared as previously described (14).
[3H]Methyl-thymidine, Hybond
N+ membranes, and ECL Western blotting detection
system were obtained from Amersham (Little Chalfont, UK).
PhosphoPlusmapk Antibody Kit was obtained from
New England Biolabs (Beverly, MA). Sepharose-coupled
anti-phosphotyrosine and anti-phosphothreonine antibodies were obtained
from Sigma. Monoclonal anti-PI3 kinase and
anti-Raf (c-Raf-1) antibodies were obtained from
Transduction Laboratories (Lexington, KY). Lipidophor system for
lipoprotein electrophoresis was obtained from Immuno AG (Vienna,
Austria).
Isolation and culture of VSMCs.
Rat aortic VSMCs were
isolated from thoracic aortae of Wistar-Kyoto rats (6-8 weeks old,
Charles River Wiga GmbH, Sulzfeld, Germany) by enzymatic dispersion
using a slight modification of the method of Chamley et al.
(26) as previously described (27). Cells were cultured in DMEM
supplemented with 10% FCS, nonessential amino acids, 100 IU/ml
penicillin, and 100 µg/ml streptomycin at 37° in the Steri-Cult
incubator (Forma Scientific, Göttingen, Germany) in a humidified
atmosphere of 95% air/5% CO2. Cells (3 × 106) were grown in 75-cm2
flasks to confluence over 4-5 days. The purity of VSMC cultures was
confirmed by immunocytochemical localization of smooth muscle-specific
-smooth muscle actin using FITC-conjugated monoclonal
anti-
-smooth muscle actin antibodies plus a second FITC-conjugated
F(ab
)2 fragment of goat anti-mouse
immunoglobulins. Experiments were performed using cells between
passages 5 and 20.
Culture of fibroblasts. Normal and FH-homozygote fibroblasts were obtained from Human Genetic Mutant Cell Repository Institute for Medical Research (Camden, NJ) and cultured over several passages after detachment of the confluent cells with Puck's Saline A physiological solution containing 0.04% trypsin/0.02% EDTA buffer. The cells were allowed to grow as described for VSMCs.
LDL isolation.
LDL (d = 1.019-1.063 g/ml) was isolated
from the plasma of four normocholesterolemic subjects (serum
cholesterol < 6.2 mM) by KBr density-gradient
ultracentrifugation according to Redgrave et al. (28). The
LDL fraction was dialyzed against 0.15 M NaCl containing 1 mM EDTA. No oxidation of LDL was observed for
4 weeks
after LDL preparation as assessed by measurement of malondialdehyde according to the thiobarbituric acid method as previously described (11). Quantification of LDL was performed by determination of the
protein component according to the method of Bradford (29). The purity
of LDL was examined with a commercially available lipoprotein electrophoresis kit (Lipidophor AII In 12; Immuno AG) after 1% agarose
electrophoresis according to the manufacturer's protocol as previously
described (30).
Measurement of [Ca2+]i.
VSMCs were
cultured onto round glass microscope slides (diameter, 12 mm) under
normal tissue culture conditions until confluence. Cells were incubated
with 2 µM Fura-2/pentaacetoxymethyl ester at 37° for 20 min in HEPES buffer supplemented with 1% bovine serum albumin (w/v).
Just before measurements were made, the cell monolayer was rinsed with
HEPES buffer without bovine serum albumin, containing 1 mM
CaCl2, and the glass slide was positioned
diagonally in the cuvette. Measurements were performed in HEPES buffer
containing 1 mM CaCl2. The
Ca2+/Fura-2 fluorescence was measured at 37° in
a Perkin-Elmer LS50 fluorescence spectrofluorometer (Überlingen,
Germany) at excitation wavelengths of 340 and 380 nm and at an emission
wavelength of 505 nm. Maximum (Rmax) and minimum
(Rmin) fluorescence values were determined by the
addition of digitonin (30 µM) followed by the addition of
1% Triton X-100 (v/v) and Tris base/EGTA at a final concentration of
100 mM Tris base/25 mM EGTA. Fluorescence was
corrected for cellular autofluorescence. Fluorescence signals were
calibrated according to Grynkiewicz et al. (31) using the following equation:
[Ca2+]i = Kd × (R
Rmin)/(Rmax
R) × (Sf2/Sb2), where the Kd value for the
Fura-2/Ca2+ complex at 37° is assumed to be 224 nM; Sf2 is the 380 nm-exited fluorescence in the
absence of Ca2+ (EGTA added), and Sb2 is the 380 nm-excited fluorescence in the presence of saturating
Ca2+ (1 mM
Ca2+).
Gel electrophoresis and immunostaining.
VSMCs were seeded
onto 24-well culture plates (4 × 105
cells/well; well diameter, 12 mm) and cultivated in culture medium
until confluent. Medium was then replaced by serum-free medium
consisting of a mixture of DMEM and Ham's F-10 medium (1:1). After
another 32-hr cultivation in serum-free medium, cells were stimulated for different time periods with LDL. After removal of the medium, cells
were lysed with a 1-ml buffer containing 137 mM NaCl, 20 mM Tris·HCl, pH 6.7, 2% SDS, 2% mercaptoethanol, and 1 mM sodium orthovanadate. After 10 min at 0°, cell lysates
were centrifuged at 14,000 × g for 2 min. Then, cell
lysates were mixed with 80 µl of Sepharose-coupled
anti-phosphotyrosine antibody to immunoprecipitate PI3 kinase and Sepharose-coupled
anti-phosphothreonine antibody to immunoprecipitate Raf-1 kinase and
shaken for
2 hr at 4°. Tyrosine- and threonine-phosphorylated
proteins were eluted with 100 µl of lysis buffer containing 5 mM phenylphosphate. Then, 20 µl was mixed with sample
buffer and heated for 5 min at 95°. After separation of the proteins
in a 7.5% SDS-polyacrylamide gel, proteins were transferred to a PVDF
membrane overnight at 100 mA in a buffer containing 25 mM
Tris base, 192 mM glycine, and 20% methanol, pH 8.3. The
protein transfer was checked using Ponceau S. Enhanced
chemiluminescence detection of PI3 kinase was
performed as previously described using monoclonal
anti-PI3-kinase (1:5,000) and secondary
anti-mouse antibodies (1:10,000) (32).
Determination of DNA synthesis. The effect of LDL on [3H]thymidine incorporation into cell DNA was assessed as previously described (27).VSMCs or fibroblasts were seeded onto 24-well culture plates and grown to confluence. The medium was replaced by serum-free medium consisting of a mixture of DMEM and Ham's F-10 medium (1:1). After another 32-hr cultivation in serum-free medium, stimuli were added to the cells. Cultures were exposed to the stimulating agents for 20 hr before 3 µCi/ml [3H]thymidine was added to the serum-free medium. Four hours later, experiments were terminated by aspiration of the medium and subjection of the cultures to sequential washes with phosphate-buffered saline containing 1 mM CaCl2, 1 mM MgCl2, 10% trichloroacetic acid, and ethanol/ether (2:1, v/v). Acid-insoluble [3H]thymidine was extracted into 250 µl/dish 0.5 M NaOH, and 100 µl of this solution was mixed with 5 ml of scintillant (Ultimagold; Packard, Groningen, The Netherlands) and quantified using a liquid scintillation counter (LS 3801; Beckman, Düsseldorf, Germany). Then, 50 µl of the residual solution was prepared for the determination of protein using the BioRad protein assay according to the method of Bradford (29).
Statistics. Values are expressed as the arithmetic mean ± standard deviation. Statistical analysis of the data was performed using the one-factor analysis of variance Scheffé F test (StatView 512+, Version 1.0; Apple Computer, Cupertino, CA). Triplicate wells were analyzed for each [3H]thymidine incorporation experiment, and each experiment was performed independently at least three times. A value of p < 0.05 was considered to be statistically significant.
| |
Results |
|---|
|
|
|---|
Analysis of lipoproteins after agarose electrophoresis. The purity of LDL isolated by KBr density-gradient ultracentrifugation method (28) was examined using the Lipidophor reagent kit. Lipoprotein electrophoresis was performed in 1% agarose gel according to the manufacturer's protocol. As shown in Fig. 1 (lane 3), LDL isolated by the density-gradient ultracentrifugation method was not contaminated with HDL or VLDL. In addition, the purity of HDL (lane 2) and VLDL (lane 4) isolated by this method (28) was very high.
|
Effect of LDL on [Ca2+]i in PTX-treated and MAPTAM-treated VSMCs. As demonstrated in Fig. 2a, LDL (100 µg/ml) induced a maximal elevation in [Ca2+]i from 40 to 140 nM, with a peak occurring at 10 sec. Thereafter, [Ca2+]i declined toward a stable value of 65 nM within 40 sec. Preincubation of the cells for 32 hr with PTX (100 ng/ml) resulted in a remarkable reduction of the maximal effect of LDL at 10 sec to 60 nM (Fig. 2b). Evaluation of four experiments was performed by calculating the maximal increase in [Ca2+]i at 10 sec. LDL at a concentration of 100 µg/ml caused an increase in [Ca2+]i from 42 ± 10 (basal value) to 145 ± 15 nM. The effect of LDL in PTX-treated cells was significantly reduced to 60 ± 15 nM (mean ± standard deviation, four experiments, p < 0.05). The ability of MAPTAM, which is known to be a potent intracellular chelator of Ca2+, to bind the LDL-induced increase in [Ca2+]i was examined after stimulation of MAPTAM-treated cells with 100 µg/ml LDL. As demonstrated in Fig. 2c, the LDL-induced increase in intracellular free Ca2+ was completely abolished in MAPTAM-treated VSMCs. MAPTAM was not able to abolish the effect of the detergent digitonin, which allows equilibration of extracellular and intracellular Ca2+.
|
Effect of LDL on the phosphorylation of MAP kinase isoforms in VSMCs and human skin fibroblasts. Activation of p44mapk and p42mapk is accompanied by phosphorylation of the Tyr204 residue (33). When VSMCs were stimulated with LDL (100 µg/ml), maximal stimulation of the p44mapk and p42mapk occurred at 5 min (Fig. 3A, top). Densitometric analysis of the blot revealed that at 5 min, LDL induced an 8-fold increase in both isoforms above control levels (Fig. 3A, bottom). No stimulation of either isoform could be observed after 30 min. Parallel cell stimulation with PDGF-BB for 5 min resulted in a 12-fold increase in the phosphorylated isoforms (Fig. 3A, top). As demonstrated in Fig. 3B (top left), the LDL-induced phosphorylation of each isoform was dose dependent. Densitometric analysis of the blot indicated that the maximal effect was achieved with 20 µg/ml LDL (Fig. 3B, bottom). To elucidate whether the LDL-induced increase in [Ca2+]i is implicated in the activation of the MAP kinase isoforms, VSMCs were preincubated for 60 min with 20 µM MAPTAM, which is known to be a potent intracellular chelator of intracellular Ca2+. As shown in Fig. 3B (top right and center), pretreatment of VSMCs with MAPTAM resulted in a 2-fold increase in the LDL-dependent effects on phosphorylation of the MAP kinase isoforms (=100%).
|
Effect of LDL on PI3 kinase. Activation PI3 kinase is accompanied by phosphorylation of several tyrosine residues. As indicated in Fig. 4, analysis of anti-tyrosine-precipitated proteins using anti-PI3 kinase antibodies showed that LDL (100 µg/ml) failed to stimulate phosphorylation of the PI3 kinase. In contrast, parallel stimulation with PDGF-BB (50 ng/ml) induced a remarkable phosphorylation of PI3 kinase at 3 and 5 min (Fig. 4).
|
Effect of LDL on the phosphorylation of Raf-1 kinase. Activation of the protein kinase Raf-1 is accompanied by phosphorylation of several serine/threonine residues. As demonstrated in Fig. 5, analysis of anti-threonine-precipitated proteins using anti-Raf-1 antibodies showed that LDL (100 µg/ml) failed to stimulate threonine phosphorylation of Raf-1.
|
Effect of LDL on DNA synthesis in VSMCs and human fibroblasts. As demonstrated in Fig. 6A, treatment of the cells with PTX (100 ng/ml) for 32 hr resulted in a complete inhibition of the LDL- and LPA-induced [3H]thymidine incorporation but failed to inhibit the effect of PDGF-BB. To demonstrate whether binding of [Ca2+]i with MAPTAM influences VSMC DNA synthesis, the effect of LDL on [3H]thymidine incorporation in MAPTAM-treated cells was investigated. As demonstrated in Fig. 6B, blocking of the LDL-induced increase in [Ca2+]i did not influence LDL-induced VSMC DNA synthesis. Similar results were obtained using normal (Fig. 6C) and FH (Fig. 6D) fibroblasts. Again, treatment of both types of fibroblasts with PTX for 32 hr resulted in a complete inhibition of the LDL- and LPA-induced DNA synthesis in both cell types.
|
Effect of PD 98059 on LDL-induced phosphorylation of p44mapk and p42mapk and DNA synthesis in VSMCs. Finally, to ensure that the mitogenic effect of LDL is mediated by activation of the MAP kinase pathway, the effect of LDL on the MAP kinase activation and DNA synthesis was investigated after treatment of VSMCs with PD 98059. As shown in Fig. 7, treatment of VSMCs with the specific MEK inhibitor PD 98059 remarkably inhibited the LDL-induced phosphorylation of both MAP kinase isoforms (Fig. 7). Treatment of the cells with 20 µM PD 98059 resulted in a 71 ± 6% inhibition of phosphorylation of the p44mapk isoform and 65 ± 6% inhibition of phosphorylation of the p44mapk isoform. In accordance with these findings, treatment of the cells with PD 98059 caused a 62% inhibition of the LDL-induced DNA synthesis in VSMCs (Fig. 8). Furthermore, PD 98059 induced a 32% inhibition of basal DNA synthesis.
|
|
| |
Discussion |
|---|
|
|
|---|
We found that the Raf-1 pathway is not involved in LDL-induced
stimulation of MAP kinase isoforms. Pretreatment of VSMCs with PTX
abolished the LDL-induced activation of MAP kinases and significantly reduced LDL-induced increase in
[Ca2+]i. A
Gi-dependent stimulation of MAP kinase without
involvement of the Raf-1 pathway has been repeatedly described in
different cell types and species (21). Recently, we found that
stimulation of PTX-treated cells with LPA (5 µg/ml) resulted in 80%
inhibition of the maximal LPA-induced increase in
[Ca2+]i occurring at
~15 sec (34). In contrast, PTX treatment of VSMCs did not influence
the PDGF-BB-induced increase in
[Ca2+]i.1
In accordance with these findings, the mitogenic effect of LDL on the
PTX-treated cells was completely abolished. Similarly, we found that
the LPA-induced activation of MAP kinase isoforms as well as the
stimulation of DNA synthesis in VSMCs and human fibroblasts is mediated
by a PTX-sensitive G protein. Because intrinsic GTPase activity of the
Gi subfamily can be inhibited by PTX via
ADP-ribosylation of specific residues, it can be postulated that LDL
promotes DNA synthesis in VSMCs via a Gi-mediated
pathway. Entire inactivation of PTX-sensitive Gis
was shown by [32P]ADP-ribosylation of isolated
VSMC membranes from PTX-treated and untreated cells as previously
described (27). Activation of VSMCs with LDL was not associated with
phosphorylation by the PI3 kinase. LDL also
failed to stimulate tyrosine phosphorylation of
PLC-
1.2 Furthermore,
treatment of VSMCs with PTX had no effect on the PDGF-BB-induced
stimulation of MAP kinase isoforms,
[Ca2+]i, and DNA
synthesis. These findings suggest that the LDL-induced intracellular
mechanisms causing an increase in DNA synthesis are distinct from those
induced by other potent VSMC mitogens, such as PDGF-BB.
It has been repeatedly described that LPA and thrombin activate the PI turnover-signaling system in hamster lung fibroblasts (CCL39) and Rat-1 cells through activation of phospholipase C. Furthermore, it has been demonstrated that the mitogenic effect of both agonists in CCL39 and Rat-1 cells is strongly attenuated by PTX treatment, suggesting that Gis are involved in the mitogenic effect of both agonists (24). Moreover, both agonists caused a PTX-sensitive activation of p21ras. On the basis of these results, it has been proposed that both agonists promote DNA synthesis via a Gi-regulated p21ras pathway and that activation of the PI-signaling system by LPA or thrombin is not involved in their growth-promoting effects (24). The concept of this novel mitogenic signaling pathway mediated by certain Gis is supported by the findings of Goodemoto et al. (35) that a PTX-sensitive G protein is also involved in the mitogenic signaling pathway of sphingosine-1-phosphate in Swiss 3T3 fibroblasts and that sphingosine-1-phosphate-induced stimulation of the PI turnover-signaling system is not essential for its mitogenic effects. Indeed, mitogenic signal transduction through a PTX-sensitive Gi/p21ras pathway is established for several agonists; thus, it is likely that a Gi-regulated/p21ras pathway is involved in the mitogenic signaling pathway of LDL.
One interesting observation was that prevention of the LDL-induced increase in [Ca2+]i by the intracellular chelator of Ca2+, MAPTAM, resulted in a 2-fold increase in the phosphorylated MAP kinase isoforms but not in an attenuation of LDL-induced DNA synthesis. Because it is believed that MAP kinase phosphatase-1 dephosphorylates and inactivates MAP kinases (36), we speculate that the LDL-induced rapid increase in [Ca2+]i is implicated in the regulation of a MAP kinase phosphatase-1.
Furthermore, we have shown that treatment of VSMCs with MAPTAM resulted in an abolishment of the LDL-induced transient increase in [Ca2+]i but failed to inhibit LDL-induced DNA synthesis. On the basis of this finding, we may suppose that the LDL-induced transient increase in [Ca2+]i alone is not sufficient to stimulate DNA synthesis and that conjugation with other signaling components, such as MAP kinase, may be necessary for a mitogenic response.
We demonstrated that LDL induces elevation in [Ca2+]i and stimulates the Na+/H+ antiport in normal and FH fibroblasts (37). In the current study, we have shown that LDL induces activation of p44mapk and p42mapk as well as DNA synthesis in normal and FH fibroblasts, which failed to produce classic LDL receptor via a PTX-sensitive pathway. Furthermore, inhibition of MEK by PD 98059 resulted in an inhibition of the activation of the MAP kinase isoforms as well as cell DNA synthesis. Thus, we may postulate that the intracellular signaling transduction pathway and the mitogenic effect of LDL are independent of its classic receptor but are mediated by a putative Gi-coupled receptor. Stimulation of this receptor causes a Raf-1-independent stimulation of p44mapk and p42mapk that results in an increase in DNA synthesis.
There is some evidence supporting our concept that the mitogenic signaling pathway of LDL is not mediated by its classic receptor but instead through a putative Gi-coupled receptor. For example, an atypical LDL binding site on human VSMCs with a Kd value of 50 µg/ml has been characterized that may mediate the LDL-induced phosphoinositide catabolism in VSMCs (12). The authors demonstrated that the atypical low affinity receptor in these cells may mediate the LDL-induced signal transduction, including stimulation of the phosphoinositide catabolism and elevation in [Ca2+]i (12). Thus, the effects of LDL on MAP kinase activation and cell DNA synthesis may be mediated by this atypical LDL receptor.
We suggest our findings are relevant to in vivo physiology and pathophysiology. In this context, it has been proposed that most of circulating LDL is transported through vascular endothelium by transcytosis via plasmalemma vesicles, which deliver LDL to other cells of the vascular wall (38). It is likely that LDL contributes physiologically to VSMCs or fibroblasts growth via a MAP kinase pathway. Cardiovascular risk factors such as hypertension and hypercholesterolemia induce an elevation in LDL transport from blood in the rat aortic intima (39). Furthermore, injection of animals with vasoactive agonists such as serotonin, angiotensin II, and catecholamines resulted in an increased transfer of LDL from blood to rat arterial vessels (40). Thus, it is conceivable that under pathophysiological conditions, elevated LDL in the aortic intima leads to abnormal VSMC growth via a MAP kinase pathway and thus may contribute to the development and acceleration of cardiovascular diseases. Because it is believed that minimally oxidized LDL is involved in the pathogenesis of atherosclerosis and native LDL can be minimally oxidized by endothelial cells, it is likely that minimally oxidized LDL is able to exert similar effects in VSMCs.
In summary, we attempted to elucidate the intracellular pathways involved in the LDL-induced DNA synthesis and postulate that like LPA, the growth-promoting effect of LDL is mediated by a putative Gi-coupled receptor and probably involves activation of MAP kinases.
| |
Footnotes |
|---|
Received March 19, 1997; Accepted May 22, 1997
1 A. Sachinidis, S. Seewald, P. Epping, C. Seul, Y. Ko, and H. Vetter, unpublished observations.
2 A. Sachinidis, S. Seewald, P. Epping, C. Seul, Y. Ko, and H. Vetter, unpublished observations.
This work was supported by Deutsche Forschungsgemeinschaft Grant Sa568/2-1.
Send reprint requests to: PD Dr. A. Sachinidis, Medizinische Universitäts-Poliklinik, Wilhelmstr. 35-37, 53111 Bonn, Germany. E-mail: umm501{at}ibm.rhrz.uni-bonn.de
| |
Abbreviations |
|---|
VSMC, vascular smooth muscle cell;
LDL, low-density lipoprotein;
HDL, high-density lipoprotein;
VLDL, very
low-density lipoprotein;
PDGF, platelet-derived growth factor;
LPA, lysophosphatidic acid;
DMEM, Dulbecco's modified Eagle's medium;
MAP, mitogen-activated protein;
PLC, phospholipase C;
FCS, fetal calf serum;
PI3, phosphatidylinositol-3;
PTX, pertussis toxin;
SDS, sodium dodecyl sulfate;
PAGE, polyacrylamide gel electrophoresis;
MEK, mitogen-activated protein kinase kinase;
[Ca2+]i, intracellular free Ca2+
concentration;
MAPTAM, bis(2-amino-5-methylphenoxy)ethane-N,N,N
,N
-tetraacetic
acid tetraacetoxymethyl ester;
FITC, fluorescein isothiocyanate;
PVDF, polyvinylidene difluoride;
FH, familial hypercholesterolemia;
HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid;
EGTA, ethylene
glycol bis(
-aminoethyl
ether)-N,N,N
,N
-tetraacetic
acid.
| |
References |
|---|
|
|
|---|
| 1. |
Schwartz, S. M.,
G. R. Campbell, and
J. H. Campbell.
Replication of smooth muscle cells in vascular disease.
Circ. Res.
58:427-444 (1986) |
| 2. | Ross, R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Mol. Pharmacol. 362:801-809 (1993). |
| 3. |
Brown, S. M. and
L. J. Goldstein.
A receptor-mediated pathway for cholesterol homeostasis.
Science (Washington D. C.)
232:34-37 (1986) |
| 4. | Martin, M. J., S. B. Hulley, W. S. Browner, L. H. Kuller, and D. Wentworth. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361 662 men. Lancet 2:933-936 (1986)[Medline]. |
| 5. |
Scott-Burden, T.,
T. J. Resink,
A. W. Hahn,
U. Baur,
R. J. Box, and
F. R. Buehler.
Induction of growth-related metabolism in human vascular smooth muscle cells by low density lipoprotein.
J. Biol. Chem.
264:12582-12589 (1989) |
| 6. |
Sachinidis, A.,
T. Mengden,
R. Locher,
C. Brunner, and
W. Vetter.
Novel cellular activities for low-density lipoprotein in vascular smooth muscle cells.
Hypertension (Dallas)
15:704-711 (1990) |
| 7. | Sachinidis, A., Y. Ko, A. Wieczorek, B. Weisser, R. Locher, W. Vetter, and H. Vetter. Lipoprotein induce expression of the early growth response gene-1 in vascular smooth muscle cells from rat. Biochem. Biophys. Res. Commun. 192:794-799 (1993)[Medline]. |
| 8. | Libby, P., P. Miao, J. M. Ordovas, and E. J. Schäfer. Lipoproteins increase growth and mitogen stimulated arterial smooth muscle cell. J. Cell Physiol. 124:1-8 (1985)[Medline]. |
| 9. | Chen, J. K., H. Hoshi, D. B. McClure, and W. L. McKeehan. Role of lipoproteins in growth of human adult arterial endothelial and smooth muscle cells in low lipoprotein-deficient serum. J. Cell Physiol. 129:207-214 (1985). |
| 10. |
Sachinidis, A.,
M. Liu,
A-A. Weber,
C. Seul,
V. Harth,
S. Seewald,
Y. Ko, and
H. Vetter.
Cholesterol enhances PDGF-BB-induced [Ca2+]i and DNA synthesis in rat aortic smooth muscle cells.
Hypertension (Dallas)
29:326-333 (1997) |
| 11. | Ko, Y., G. Totzke, S. Seewald, U. Schmitz, B. Schiermeyer, M. Meyer zu Brickwedde, H. Vetter, and A. Sachinidis. Native low-density lipoprotein (LDL) induces the expression of the early-growth response gene-1 in human umbilical arterial endothelial cells. Eur. J. Cell Biol. 68:306-312 (1995)[Medline]. |
| 12. | Tkachuk, V. A., Y. S. Kuzmenko, T. J. Resink, D. V. Stambolsky, and V. N. Bochkov. Atypical low density lipoprotein binding site that may mediate lipoprotein-induced signal transduction. Mol. Pharmacol. 46:1129-1137 (1994)[Abstract]. |
| 13. | Ross, R., E. W. Raines, and D. F. Bowen-Pope. The biology of platelet-derived growth factor. Cell 46:155-169 (1986)[Medline]. |
| 14. |
Sachinidis, A.,
R. Locher,
W. Vetter,
D. Tatje, and
J. Hoppe.
Different effects of PDGF-isoforms on rat vascular smooth muscle cells.
J. Biol. Chem.
265:10238-10234 (1990) |
| 15. |
Kaplan, D. R.,
D. K. Morrison,
G. Wong,
F. McCormic, and
L. Williams.
PDGF -receptor stimulates tyrosine phosphorylation of GAP and association of GAP with a signaling complex.
Cell
61:125-133 (1990)[Medline].
|
| 16. |
Rönnstrand, L.,
S. Mori,
A. K. Arridson,
A. Erikssen,
C. Wernstedt,
U. Hellman,
L. Claesson-Welsh, and
C. H. Heldin.
Identification of two C-terminal autophosphorylation sites in the PDGF- -receptor: involvement in the interaction with phospholipase C- .
EMBO. J.
11:3911-3919 (1992)[Medline].
|
| 17. | Peters, K. G., J. Marie, E. Wilson, H. E. Ives, J. Escobedo, M. Delrosario, D. Mirda, and L. T. Williams. Point mutation of an EGF receptor abolishes phosphatidylinositol turnover and Ca2+ flux but not mitogenesis. Nature (Lond.) 358:678-681 (1992)[Medline]. |
| 18. |
Kazlauskas, A.,
A. Kashishian,
J. A. Cooper, and
M. Valius.
GTPase-activating protein and phosphatidylinositol 3-kinase bind to distinct regions of the platelet-derived growth factor receptor -subunit.
Mol. Cell. Biol.
12:5078-5086 (1992) |
| 19. |
Klippel, A.,
J. A. Escobedo,
W. J. Fantl, and
L. T. Williams.
The C-terminal SH2 domain of p85 accounts for the high affinity and specificity of the binding of phosphatidyl 3-kinase to phosphorylated platelet-derived growth factor- -receptor.
Mol. Cell. Biol.
12:1451-1459 (1992) |
| 20. |
Pelech, S. L. and
S. Sanghera.
MAP Kinases: Charting the Regulatory Pathways.
Science (Washington D. C.)
257:1355-1356 (1992) |
| 21. |
Blenis, J.
Signal transduction via the MAP kinases: Proceed at your own RSK.
Proc. Natl. Acad. Sci. USA
90:5889-5892 (1993) |
| 22. | Pouysségur, J. and K. Seuwen. Transmembrane receptors and intracellular pathways that control cell proliferation. Annu. Rev. Physiol. 54:195-210 (1992)[Medline]. |
| 23. | van Corven, E. J., A. Groenik, K. Jalink, T. Eichholz, and W. H. Moolenaar. Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathway mediated by G proteins. Cell 59:45-54 (1989)[Medline]. |
| 24. |
van Corven, E. J.,
P. L. Hordijk,
R. H. Medema,
J. L. Bos, and
W. H. Moolenaar.
Pertussis toxin-sensitive activation of p21ras by G protein-coupled receptor agonists in fibroblasts.
Proc. Natl. Acad. Sci. USA
90:1257-1261 (1993) |
| 25. |
Dudley, D. T.,
L. Pang,
S. J. Decker,
A. J. Bridges, and
A. R. Saltiel.
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Proc. Natl. Acad. Sci. USA
92:7686-7689 (1995) |
| 26. | Chamley, J. H., G. R. Campbell, and R. Ross. The smooth muscle cell in culture. Physiol. Rev. 39:1-61 (1979). |
| 27. |
Sachinidis, A.,
M. Flesch,
Y. Ko,
K. Schrör,
M. Böhm,
R. Düsing, and
H. Vetter.
Thromboxane A2 and vascular smooth muscle cell proliferation.
Hypertension (Dallas)
26:771-780 (1995) |
| 28. | Redgrave, T. G., D. C. K. Robert, and C. E. West. Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal. Biochem. 65:42-49 (1975)[Medline]. |
| 29. | Bradford, M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254 (1976)[Medline]. |
| 30. | Wieland, H. and D. Seidel. Advances in the analysis of plasma lipoproteins. Innere Medizin 7:290-300 (1978). |
| 31. | Grynkiewicz, G., M. Poenie, and R. Y. Tsien. A new generation of Ca2+ indicators with greatly improved fluorescence properties. Trends Biochem. Sci. 260:3440-3450 (1985). |
| 32. | Sachinidis, A., R. Kraus, C. Seul, M. K. Meyer zu Brickwedde, K. B. Schulte, Y. Ko, J. Hoppe, and H. Vetter. Gangliosides GM1, GM2, and GM3 inhibit the platelet-derived growth factor-induced signalling transduction pathway in vascular smooth muscle cells by different mechanisms. Eur J. Cell Biol. 71:79-88 (1996)[Medline]. |
| 33. | Marshall, C. J. Specifity of receptor tyrosine kinase signaling:transient versus sustained extracellular signal-regulated kinase activation. Cell 80:179-185 (1995)[Medline]. |
| 34. | Seewald, S., A. Sachinidis, R. Düsing, Y. Ko, C. Seul, P. Epping, and H. Vetter. Lysophosphatidic acid and intracellular signalling in vascular smooth muscle cells. Atherosclerosis 130:121-131 (1997)[Medline]. |
| 35. |
Goodemoto, K. A.,
M. E. Mattie,
A. Berger, and
S. Spiegel.
Involvement of a pertussis toxin-sensitive G protein in the mitogenic signaling pathways of sphingosine 1-phosphate.
J. Biol. Chem.
270:10272-10277 (1995) |
| 36. | Sun, H., C. H. Charles, L. F. Lau, and N. K. Tonks. MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell 75:487-493 (1993)[Medline]. |
| 37. | Sachinidis, A., R. Locher, T. Mengden, and W. Vetter. Low-density lipoprotein elevates intracellular calcium and pH in vascular smooth muscle cells and fibroblasts without mediation of LDL receptor. Biochem. Biophys. Res. Commun. 167:353-359 (1990)[Medline]. |
| 38. |
Vasile, E.,
M. Simionescu, and
N. Simionescu.
Visualization of the binding, endocytosis, and transcytosis of low-density lipoprotein in arterial endothelium in situ.
J. Cell Biol.
96:1677-1689 (1983) |
| 39. |
Daly, M. M.
Effect of hypertension on the lipid composition of rat aortic intima-media.
Circ. Res.
31:410-416 (1972) |
| 40. | Robertson, A. L and P. A. Khairallah. Arterial endothelial permeability and vascular diseases, the `trap door' effect. Exp. Mol. Pathol. 18:241-260 (1973)[Medline]. |
This article has been cited by other articles:
![]() |
N. Bulat, G. Waeber, and C. Widmann LDLs stimulate p38 MAPKs and wound healing through SR-BI independently of Ras and PI3 kinase J. Lipid Res., January 1, 2009; 50(1): 81 - 89. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Crespo, J. Martinez-Gonzalez, J. Rius, and L. Badimon Simvastatin inhibits NOR-1 expression induced by hyperlipemia by interfering with CREB activation Cardiovasc Res, August 1, 2005; 67(2): 333 - 341. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-Y. Tu, M. C. Cheung, X. Zhu, R. H. Knopp, and J. J. Albers Low-Density Lipoprotein Inhibits Secretion of Phospholipid Transfer Protein in Human Trophoblastic BeWo Cells Experimental Biology and Medicine, November 1, 2004; 229(10): 1046 - 1052. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Rius, J. Martinez-Gonzalez, J. Crespo, and L. Badimon Involvement of Neuron-Derived Orphan Receptor-1 (NOR-1) in LDL-Induced Mitogenic Stimulus in Vascular Smooth Muscle Cells: Role of CREB Arterioscler. Thromb. Vasc. Biol., April 1, 2004; 24(4): 697 - 702. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Dobreva, G. Waeber, V. Mooser, R. W. James, and C. Widmann LDLs induce fibroblast spreading independently of the LDL receptor via activation of the p38 MAPK pathway J. Lipid Res., December 1, 2003; 44(12): 2382 - 2390. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-W. Chien, C.-S. Chien, L.-D. Hsiao, C.-H. Lin, and C.-M. Yang OxLDL induces mitogen-activated protein kinase activation mediated via PI3-kinase/Akt in vascular smooth muscle cells J. Lipid Res., September 1, 2003; 44(9): 1667 - 1675. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. GOUNI-BERTHOLD and A. SACHINIDIS Does the coronary risk factor low density lipoprotein alter growth and signaling in vascular smooth muscle cells? FASEB J, October 1, 2002; 16(12): 1477 - 1487. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Velarde, A. J. Jenkins, J. Christopher, T. J. Lyons, and A. A. Jaffa Activation of MAPK by modified low-density lipoproteins in vascular smooth muscle cells J Appl Physiol, September 1, 2001; 91(3): 1412 - 1420. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Metzler, Y. Hu, H. Dietrich, and Q. Xu Increased Expression and Activation of Stress-Activated Protein Kinases/c-Jun NH2-Terminal Protein Kinases in Atherosclerotic Lesions Coincide with p53 Am. J. Pathol., June 1, 2000; 156(6): 1875 - 1886. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hu, H. Dietrich, B. Metzler, G. Wick, and Q. Xu Hyperexpression and Activation of Extracellular Signal-Regulated Kinases (ERK1/2) in Atherosclerotic Lesions of Cholesterol-Fed Rabbits Arterioscler. Thromb. Vasc. Biol., January 1, 2000; 20(1): 18 - 26. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sachinidis, R. Kettenhofen, S. Seewald, I. Gouni-Berthold, U. Schmitz, C. Seul, Y. Ko, and H. Vetter Evidence That Lipoproteins Are Carriers of Bioactive Factors Arterioscler. Thromb. Vasc. Biol., October 1, 1999; 19(10): 2412 - 2421. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Metzler, C. Li, Y. Hu, G. Sturm, N. Ghaffari-Tabrizi, and Q. Xu LDL Stimulates Mitogen-Activated Protein Kinase Phosphatase-1 Expression, Independent of LDL Receptors, in Vascular Smooth Muscle Cells Arterioscler. Thromb. Vasc. Biol., August 1, 1999; 19(8): 1862 - 1871. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Iaccarino, L. A. Smithwick, R. J. Lefkowitz, and W. J. Koch Targeting Gbeta gamma signaling in arterial vascular smooth muscle proliferation: A novel strategy to limit restenosis PNAS, March 30, 1999; 96(7): 3945 - 3950. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Auge, I. Escargueil-Blanc, I. Lajoie-Mazenc, I. Suc, N. Andrieu-Abadie, M.-T. Pieraggi, M. Chatelut, J.-C. Thiers, J.-P. Jaffrezou, G. Laurent, et al. Potential Role for Ceramide in Mitogen-activated Protein Kinase Activation and Proliferation of Vascular Smooth Muscle Cells Induced by Oxidized Low Density Lipoprotein J. Biol. Chem., May 22, 1998; 273(21): 12893 - 12900. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Seewald, C. Seul, R. Kettenhofen, D. Bokemeyer, Y. Ko, H. Vetter, and A. Sachinidis Role of Mitogen-Activated Protein Kinase in the Angiotensin II–Induced DNA Synthesis in Vascular Smooth Muscle Cells Hypertension, May 1, 1998; 31(5): 1151 - 1156. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Zhao, J. Letterman, and B. M. Schreiber beta -Migrating Very Low Density Lipoprotein (beta VLDL) Activates Smooth Muscle Cell Mitogen-activated Protein (MAP) Kinase via G Protein-coupled Receptor-mediated Transactivation of the Epidermal Growth Factor (EGF) Receptor. EFFECT OF MAP KINASE ACTIVATION ON beta VLDL PLUS EGF-INDUCED CELL PROLIFERATION J. Biol. Chem., August 10, 2001; 276(33): 30579 - 30588. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||